JP2024056938A5 - - Google Patents

Download PDF

Info

Publication number
JP2024056938A5
JP2024056938A5 JP2024022697A JP2024022697A JP2024056938A5 JP 2024056938 A5 JP2024056938 A5 JP 2024056938A5 JP 2024022697 A JP2024022697 A JP 2024022697A JP 2024022697 A JP2024022697 A JP 2024022697A JP 2024056938 A5 JP2024056938 A5 JP 2024056938A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
polynucleotide
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024022697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024056938A (ja
Filing date
Publication date
Priority claimed from PCT/CN2019/088013 external-priority patent/WO2019223733A1/en
Application filed filed Critical
Publication of JP2024056938A publication Critical patent/JP2024056938A/ja
Publication of JP2024056938A5 publication Critical patent/JP2024056938A5/ja
Withdrawn legal-status Critical Current

Links

JP2024022697A 2018-05-23 2024-02-19 抗ox40抗体及び使用方法 Withdrawn JP2024056938A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/088101 2018-05-23
CN2018088101 2018-05-23
PCT/CN2019/088013 WO2019223733A1 (en) 2018-05-23 2019-05-22 Anti-ox40 antibodies and methods of use
JP2020565492A JP7489922B2 (ja) 2018-05-23 2019-05-22 抗ox40抗体及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020565492A Division JP7489922B2 (ja) 2018-05-23 2019-05-22 抗ox40抗体及び使用方法

Publications (2)

Publication Number Publication Date
JP2024056938A JP2024056938A (ja) 2024-04-23
JP2024056938A5 true JP2024056938A5 (https=) 2024-10-17

Family

ID=68615676

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565492A Active JP7489922B2 (ja) 2018-05-23 2019-05-22 抗ox40抗体及び使用方法
JP2024022697A Withdrawn JP2024056938A (ja) 2018-05-23 2024-02-19 抗ox40抗体及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020565492A Active JP7489922B2 (ja) 2018-05-23 2019-05-22 抗ox40抗体及び使用方法

Country Status (14)

Country Link
US (2) US12103974B2 (https=)
EP (1) EP3797123A4 (https=)
JP (2) JP7489922B2 (https=)
KR (1) KR20210013708A (https=)
CN (1) CN112566935B (https=)
AU (1) AU2019272384A1 (https=)
BR (1) BR112020023746A2 (https=)
EA (1) EA202092460A1 (https=)
IL (1) IL278772A (https=)
MX (2) MX2020012567A (https=)
SG (1) SG11202011024WA (https=)
TW (1) TW202016133A (https=)
WO (1) WO2019223733A1 (https=)
ZA (1) ZA202006931B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
WO2021098750A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
US20230022859A1 (en) * 2019-11-21 2023-01-26 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
US20230002500A1 (en) * 2019-11-21 2023-01-05 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Pi3キナーゼデルタ阻害剤との組合せで抗ox40抗体を用いる癌治療の方法
US20230212291A1 (en) * 2019-11-21 2023-07-06 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
JP2023503399A (ja) * 2019-11-21 2023-01-30 ベイジーン リミテッド 抗tim3抗体と組み合わせて抗ox40抗体を用いるがんを治療する方法
PE20230682A1 (es) * 2020-04-17 2023-04-21 Hutchison Medipharma Ltd Anticuerpo anti-ox40 y usos del mismo
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技(北京)有限公司 结合ox40的抗体或抗原结合片段
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ox40抗体及び使用方法
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
CN120476146A (zh) * 2022-12-30 2025-08-12 甘李药业股份有限公司 抗ox40抗体及其应用
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
TW202436354A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗cldn6抗體以及其使用方法
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
WO2024240247A1 (en) * 2023-05-25 2024-11-28 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ox40之抗體

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
BRPI0816064B8 (pt) 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
HUE036157T2 (hu) * 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
SMT201700185T1 (it) * 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
CN102010407A (zh) 2010-11-16 2011-04-13 上海科胜药物研发有限公司 一种合成达沙替尼的新方法
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
SMT201800503T1 (it) 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
EP3126394B1 (en) 2014-03-31 2019-10-30 F.Hoffmann-La Roche Ag Anti-ox40 antibodies and methods of use
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
MX2017011194A (es) * 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
PT3274370T (pt) 2015-03-23 2020-01-30 Bayer Pharma AG Anticorpos anti-ceacam6 e utilizações dos mesmos
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
KR20180011839A (ko) 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
WO2017063162A1 (zh) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CA3032952A1 (en) * 2016-08-08 2018-02-15 Sorrento Therapeutics, Inc. Anti-ox40 binding proteins
US11203637B2 (en) 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
KR102769109B1 (ko) 2017-11-24 2025-02-18 유큐(베이징) 바이오파마 코., 엘티디 항―ox40 항체 및 그의 용도
CN110092832B (zh) 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
MX2020012081A (es) 2018-05-11 2021-04-28 Wuxi Biologics Shanghai Co Ltd Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
JP2023503399A (ja) 2019-11-21 2023-01-30 ベイジーン リミテッド 抗tim3抗体と組み合わせて抗ox40抗体を用いるがんを治療する方法
JP2023503230A (ja) 2019-11-21 2023-01-27 ベイジーン リミテッド Pi3キナーゼデルタ阻害剤との組合せで抗ox40抗体を用いる癌治療の方法
US20230002500A1 (en) 2019-11-21 2023-01-05 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
US20230212291A1 (en) 2019-11-21 2023-07-06 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098750A1 (en) 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
US20230022859A1 (en) 2019-11-21 2023-01-26 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2024056938A5 (https=)
JP2021524256A5 (https=)
JP7241207B2 (ja) Tigitおよびpd-1/tigit結合分子
US20160159912A1 (en) Combination therapy of anti-her3 antibodies
US11939381B2 (en) Bispecific antibodies targeting immune checkpoints
CN105968206A (zh) 抗erbb3抗体
JPWO2019223733A5 (https=)
JP2020522280A5 (https=)
CN116262135A (zh) 抗cd27抗体组合物及其用途
TW202413426A (zh) 抗ccr8抗體及使用方法
JP2021528439A5 (https=)
EP4180457A1 (en) Anti-cldn-18.2 antibody and use thereof
JPWO2023078382A5 (https=)
US20250171556A1 (en) Multispecific antibodies for treating cd47-associated diseases
CN114269780B (zh) 一种新型抗pd-l1抗体及其用途
JPWO2022242680A5 (https=)
JPWO2022242681A5 (https=)
AU2016203429B2 (en) Binding Molecules to the Human OX40 Receptor
HK40043144A (en) Bispecific antibodies targeting immune checkpoints
HK40114941A (zh) 用於治疗cd47相关疾病的多特异性抗体
RU2025121328A (ru) МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ TGFβ1, МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ GARP-TGFβ1, И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
RU2025101095A (ru) Способы лечения рака с помощью антител против tigit
NZ761838B2 (en) Cd38 antibody
NZ760342B2 (en) Cd38 modulating antibody
NZ761020B2 (en) Cd38 modulating antibody